|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Etanercept is a soluble tumor necrosis factor (TNF) receptor originally approved for treatment of moderate-to-severe rheumatoid arthritis, juvenile rheumatoid arthritis, and psoriatic arthritis.
|
21996051 |
2011 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TNFA and DRB I alleles were not significantly associated with PsA.
|
12022360 |
2002 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients.
|
31672774 |
2020 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective.
|
15251081 |
2004 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the last decade anti-tumor necrosis factor agents have shown to be effective for the treatment of both RA and PsA and some studies suggest that the interaction between TNFα and complement system may contribute to the pathogenesis of these diseases.
|
21549221 |
2011 |
|
Arthritis, Psoriatic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We aimed to characterize the PsA genotype by gene expression profile and to research the effect in gene modulation of methotrexate (MTX) and TNF-inhibitors (TNF-I) in PsA-treated patients.
|
25339124 |
2014 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-tumor necrosis factor-alpha (TNF-α) immunotherapy has revolutionized the treatment of inflammatory diseases, such as psoriasis and psoriatic arthritis.
|
31719235 |
2020 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently, along with traditional disease modifying anti-rheumatic drugs (DMARDs), TNF-α, IL-12/23 and IL-17 are available for treatment of such diseases as ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
|
29283375 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
For example, tumor necrosis factor inhibitors are quite successful in the treatment of rheumatoid arthritis (RA), Behçet's disease (BD), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) but not in that of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome (SS) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV), conversely, RA shares genetic backgrounds more with SLE, SSc, SS and AAV than BD, AS and PsA.
|
29623390 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.
|
30172115 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our results show that Fhl2 anticipates the emerging inflammation and specifically the development of psoriatic arthritis by impeding the Adam17-mediated release of TNF.
|
28823868 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
For this reason, TNF-alpha antagonists have become more and more important as a second-line therapy for PsA.
|
20015187 |
2010 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study aims to evaluate the drug survival and effectiveness of ustekinumab in psoriatic arthritis (PsA) patients naïve to biologics or inadequate responders to tumor necrosis factor (TNF-IR) inhibitors in real life.
|
29411182 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To evaluate the 8-year survival of the first tumor necrosis factor inhibitor (TNFi) in patients with axial spondyloarthritis (SpA) or psoriatic arthritis (PsA), identify the predictive factors for withdrawal, and compare the discontinuation rates for infliximab, etanercept, and adalimumab.
|
27696735 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also explore the role of MTX in combination therapy with tumor necrosis factor inhibitors, in addition to its safety and tolerability, to answer the question: should methotrexate have any place in the treatment of psoriatic arthritis?
|
31277747 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 54 patients with RA, 10 with PsA and 22 with AS were genotyped by polymerase chain reaction for the -308 TNFalpha promoter polymorphism.
|
16720636 |
2007 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TNF gene polymorphisms may be useful prognostic markers in PsA, and these results support the rationale for using anti-TNF treatment in patients with severe, progressive PsA.
|
12746914 |
2003 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The only difference between psoriasis and psoriatic arthritis was TNF-857.
|
24135300 |
2014 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Data were pooled from 2 phase III studies (Efficacy and Safety of Tofacitinib in Psoriatic Arthritis [OPAL Broaden] and Tofacitinib in Patients with Psoriatic Arthritis With Inadequate Response to TNF Inhibitors [OPAL Beyond]) and 1 ongoing long-term extension (Open-Label Extension Study of Tofacitinib in Psoriatic Arthritis [OPAL Balance], data cutoff January 2017; database not locked).
|
31112005 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Real-World Long-Term Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register.
|
31371659 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The current model of psoriatic arthritis implicates both the IL-23/IL-17 axis and the tumor necrosis factor (TNF) pathways in disease pathogenesis.
|
26476224 |
2015 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriatic arthritis (PsA) can be treated using biologic therapies targeting biomolecules such as tumor necrosis factor alpha, interleukins (IL)-17 and IL-23.
|
26108918 |
2016 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)-inhibitors are used to treat psoriatic arthritis (PsA), but only a limited number of observational studies on this subject have been published thus far.
|
28010883 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rheumatoid and psoriatic arthritis are chronic inflammatory diseases, with massive increase of cardiovascular events (CVE), and contribution of the cytokines TNF-α and IL-17.
|
29195855 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
373 controls and 137 SpA (82 with Psoriatic Arthritis-PsA and 55 with Ankylosing Spondylitis- AS; 98/137 under TNFα inhibitor therapy) from the Veneto Region (Italy) were studied.
|
29579081 |
2018 |